Interview with Diego López (AZ) about Precision Oncology

Diego López Mendoza, medical director of Oncology at Astrazeneca Spain.

The most cancers strategy it has developed considerably lately. The new therapies of immunotherapies and focused therapies They have meant a “radical change” for sufferers, rising their survival and high quality of life. Pharmaceutical corporations comparable to Astrazeneca. Your medical director of Oncology in Spain, Diego Lopez, analyzes these modern medicines whereas betting on the necessity for a nationwide biomarker plan “To help us better select patients to receive targeted treatments and save costs for the healthcare system”.

Astrazeneca has set itself the aim of redefining most cancers affected person care and works with the dedication to remove most cancers as a reason behind demise.

I might love to have the ability to announce someday that we now have achieved a definitive treatment for most cancers. Meanwhile, at Astrazeneca, our aim is to attain (we’re already engaged on it) to make most cancers persistent due to a radical change within the strategy to take care of these sufferers. For instance, with the looks of focused therapies and immunotherapy we now have stopped speaking merely about ‘most cancers of …’, we’re studying to characterize tumors higher and we now have launched new, extra particular remedy approaches, for instance, in lung most cancers, bile duct, breast most cancers and gastric most cancers, safer and with the next success price than we had just a few years in the past.

In this sense, considered one of our important areas of curiosity is the administration of lung most cancers, the place we’re reaching unthinkable outcomes just a few years in the past. In addition, we’re supporting initiatives to learn the way the lung most cancers screening applications to attain an early boarding. We can not overlook that, based on the most recent report from the Spanish Society of Medical Oncology (SEOM, Cancer figures in Spain, 2021), the overall variety of most cancers instances recognized every year will improve by greater than 50 p.c, from the present 19.3 million to 30.2 million new instances within the yr 2040.


“It is estimated that in 2021 alone 29,549 new cases of lung cancer have been diagnosed in Spain”


We have to be ready for this case and have a proactive strategy, with out forgetting, after all, the promotion of wholesome life-style habits. In the case of lung most cancers, it’s estimated that solely in 2021 they’ve been recognized 29,549 new instances in Spain.

How is the administration of most cancers sufferers in Spain? Where is it going? What points could be improved?

Currently, the administration of most cancers sufferers in Spain requires our dedication to supply higher options to clinicians for a lot of sorts of tumors. However, the problem stays to supply new and higher therapies, particularly in tumors which have fewer therapeutic choicescomparable to small cell lung most cancers, an instance of latest successes. But our aim goes additional. Our ‘roadmap’ is directed in the direction of the chronification of most cancers and its elimination as a reason behind demise.

Regarding the problems that may very well be improved, from Astrazeneca we wish to facilitate entry to strategies of early diagnostic, particularly in pathologies that would have a extra favorable evolution if the analysis is made as quickly as potential; for instance, in lung most cancers. In addition, from Astrazeneca we now have influenced in quite a few boards on the necessity to create a National Biomarker Plan to assist us higher choose sufferers to obtain focused therapies and save prices for the well being system. This is the results of the Precision Medicine who at present directs the scientific growth of Oncology.

To proceed advancing in Precision Medicine, it’s important that we are able to supply the perfect therapies for every affected person particular. And that’s solely potential by accurately deciding on sufferers for every kind of tumor.

How has AstraZeneca contributed to the development of medication to deal with most cancers? Has it actually elevated affected person survival for some cancers? Could you give an instance?

In latest years we’re witnessing a radical change within the strategy to most cancers. The look of immunotherapy and focused therapies has meant, typically, a rise within the survival of most cancers sufferers, and an enchancment within the high quality of life. This change has been seen particularly within the sufferers with extra aggressive and / or resistant cancers, that’s, those that needed to endure a number of strains of remedy after development. This is the case, for instance, of sufferers with most cancers of the HER2 + metastatic breast.


“The challenge is in microcritical lung cancer, a tumor that has fewer therapeutic options”



What new potentialities have immunotherapy therapies in lung most cancers opened? And, particularly, in small cell lung most cancers, the place survival may be very restricted, what has the innovation contributed?

The new mixtures of immunotherapy with chemotherapy have represented a revolution within the remedy of sufferers with lung most cancers, to the purpose that we are able to start to talk of a new paradigm of remedy. This is exactly why these outcomes are particularly encouraging, since small cell lung most cancers till now had very restricted therapeutic choices and its survival price may be very low even in comparison with non-small cell lung most cancers.

In any case, it shouldn’t be forgotten that lung most cancers usually represents 20.3 p.c of all most cancers deaths in our nation, representing a complete of twenty-two,930 deaths based on the most recent SEOM report.

Have there additionally been enhancements in molecular diagnostics?

It is what we are attempting. The analysis of lung most cancers is advanced, and most sufferers have widespread illness on the time of analysis. However, molecular evaluation of the tumor provides us the chance to characterize it and have the ability to act in a particular method relying on the kind of lung most cancers.

That is why we imagine that it is very important have the ability to supply higher molecular diagnostic companies by means of biomarkers, particularly in most cancers sorts the place early analysis and a precise tumor affiliation they could be a nice benefit.

Can we then converse of lengthy survivors in SCC? How have the brand new immunotherapy therapies modified the attitude of SCC sufferers? Do you might have any new choices?

Yes, we are able to begin speaking about lengthy survivors with small cell lung most cancers. Not way back, we barely had a therapeutic arsenal towards such a most cancers and chemotherapy was the one various out there to sufferers. However, scientific advances symbolize an ideal advance towards such a most cancers, primarily as a result of they provide us time; time for additional analysis and time for clinicians to check new therapeutic choices for the advantage of their sufferers. Small cell lung most cancers may be very aggressive, so slowing down the development of the illness is already an achievement.


“Microcritical lung cancer is very aggressive, so slowing down the progression of the disease is already an achievement in which we are making progress”



What position can Real World Evidence (RWE) play in lung most cancers?

One factor is principle and one other apply. The process for designing a scientific trial should consider all potential variables, however it’s inevitable that some kind of bias might happen, so real-life trials, the Real World Evidence (RWE), is a elementary device to confirm that the outcomes we now have obtained in scientific situations are replicable in actual life.

How do you assume most cancers medication are going to be sooner or later?

I feel the long run lies in persevering with to develop immunotherapy; proceed creating medication directed towards particular molecular targets, whereas reaching fewer unwanted side effects and higher high quality of life for sufferers. Little by little we’re getting quite a few oncological pathologies grow to be persistent ailments and that have to be achieved in all sorts of tumors, which, as is understood, are many.

Although it could include statements, knowledge or notes from well being establishments or professionals, the knowledge contained in Medical Writing is edited and ready by journalists. We advocate that the reader be consulted with any health-related query with a healthcare skilled.

Source link

About Staff

Check Also

Ombudsman visits the hospital to confirm if the rights of international ladies in labor are revered

The Ombudsman, Pablo Ulloa, visited the San Lorenzo de Los Mina Maternal and Child Hospital …

Leave a Reply

Your email address will not be published. Required fields are marked *